ViaNautis
Targeted delivery of regenerative cargo to the brain and specific tissues has been a major challenge in central nervous-system repair. Thanks to SCI Venture's investment, ViaNautis' breakthrough technology is now pointed for the first time at chronic SCI regeneration. The Cambridge (UK)-based biotech is backed by big pharma's venture arms including UCB Pharma and Eli Lilly.
How they’re delivering breakthroughs
Genetic therapeutic cargo is loaded into polymer-nanovesicles and cell-targeting ligands are conjugated to the surface of the vesicles. This way the payload is delivered to the intended site of action, such as spinal cord-lesions where the regenerative cargo is released.
How they’re making a difference
Drug delivery to the brain has been a major challenge in addressing brain and spinal disorders and hence, laboratory advances have previously struggled to translate into the clinic. ViaNautis's targeted delivery platform is designed to overcome these challenges and unlock the potential of decades of academic research and develop regenerative therapies for people living with SCI.
A top-tier management team is driving this game-changing innovation towards the clinic. CEO Dr. Adi Hoess has over 30 years of experience as biotech executive. Most recently he led Affimed from a preclinical to a clincal-stage biotech. Chief Scienific Officer Dr. Ray Jupp has developed over 10 drugs tested in the clinic.
